PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market. These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions. Leveraging the latest IVR technology, which automates the testing of drug release from formulations over
Osmotic Controlled Release Oral Drug Delivery A Closer Look pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
JSS Academy receives yet another patent for a scaffold for the treatment of diabetic wounds mauritiustimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mauritiustimes.com Daily Mail and Mail on Sunday newspapers.